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Type 2 diabetes (T2D) is associated with cardiovascular and pulmonary disease. How T2D affects 
pulmonary endothelial function is not well characterized. We investigated the effects of T2D 
progression on contractility machinery and endothelial function in the pulmonary and systemic 
circulation and the mechanisms promoting the dysfunction, using pulmonary artery (PA) and aorta. A 
high‑fat (HF, 3 weeks 60% lipid‑rich diet) and a high‑fat/high‑sucrose (HFHSu, combined 60% lipid‑rich 
diet and 35% sucrose during 25 weeks) groups were used as prediabetes and T2D rat models. We found 
that T2D progression differently affects endothelial function and vascular contractility in the aorta and 
PA, with the contractile machinery being altered in the PA and aorta in prediabetes and T2D animals; 
and endothelial function being affected in both models in the aorta but only affected in the PA of T2D 
animals, meaning that PA is more resistant than aorta to endothelial dysfunction. Additionally, PA 
and systemic endothelial dysfunction in diabetic rats were associated with alterations in the nitrergic 
system and inflammatory pathways. PA dysfunction in T2D involves endothelial wall mineralization. 
The understanding of the mechanisms behind PA dysfunction in T2D can lead to significant advances 
in both preventative and therapeutic treatments of pulmonary disease‑associated diabetes.
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Ach  Acetylcholine
AGEs  Advanced glycation end products
eNOS  Endothelial NOS
HF  High-fat
HFHSu  High fat-high sucrose
IL-1R  Interleukin 1 receptor
IL-6R  Interleukin 6 receptor
iNOS  Inducible NOS
ITT  Insulin tolerance test
NFκB  Nuclear factor kappa-light-chain-enhancer of activated B cells
NO  Nitric oxide
OGTT  Oral glucose tolerance test
PA  Pulmonary artery
PAH  Pulmonary arterial hypertension
PE  Phenylephrine
PGF2α  Prostaglandin  F2α
RAGE  Receptor for advanced glycation end products
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SD  Standard deviation
T2D  Type 2 diabetes
TNFα  Tumour necrosis factor alpha
VSM  Vascular smooth muscle
The endothelium is a physical barrier between blood and tissues, therefore controlling the exchange of molecules 
between  them1. In addition, endothelial cells produce and release several mediators, including vasodilators, 
as nitric oxide (NO) and prostacyclin, vasoconstrictors, as endothelin-1 and prostaglandin  F2α  (PGF2α), and 
substances that participate in coagulation, fibrinolysis and inflammatory and immunological reactions as well 
as reactive oxygen species (ROS) and growth factors promoting cell growth, among others. Any disturbances 
affecting the endothelium as, for example, alterations in the capacity to produce and release these substances, or 
alterations in the function of the endothelium as physical barrier may cause endothelial  dysfunction2.
Endothelial dysfunction is characterized by a reduction of the bioavailability of vasodilators whereas endothe-
lium-derived contracting factors are  increased3. This imbalance leads to vasoconstriction, leucocyte adherence, 
vascular inflammation, atherosclerosis and thrombosis, among  others4.
Impaired endothelium-dependent relaxation is well documented in type 2 diabetes (T2D), which is mainly 
caused by reduced NO bioavailability. Other factors that can contribute to endothelial dysfunction in T2D include 
a decrease in the production of other relaxing factors, an increase in the production of vasoconstrictor substances 
or a reduction in the sensitivity of vascular smooth muscle (VSM) to relaxing  factors5. One of the pathological 
characteristics of T2D is hyperglycemia together with insulin resistance and, it is known that vascular endothelial 
cells are very prone to be damaged by hyperglycemic  stress6. One of the mechanisms contributing to hypergly-
cemic-vascular damage is the increased production of advanced glycation end products (AGEs) that by biding 
to their cellular receptors augment oxidant stress and induce a state of endothelial cell activation contributing 
to endothelial  impairment7,8. Hyperglycemia also contributes to alterations in the balance between vasodilators 
and vasoconstrictors, as it enhances the secretion, in vitro, of endothelin-1 and decreases NO production in the 
aorta of diabetic rats and coronary microvessels in  humans9. IL-1 and IL-6, proinflammatory signaling molecules, 
also showed to play an important role in mediating vascular endothelial dysfunction, by exacerbating oxidative 
stress and reducing phosphorylation of  eNOS10.
Diabetes is a major risk factor of peripheral artery disease, leading to an accelerated disease course and sev-
eral  complications11. More recently, a link between diabetes, especially T2D, and the development of pulmonary 
vascular disease, particularly pulmonary arterial hypertension (PAH) which can lead to right ventricular failure 
and  death12–14 was suggested. Furthermore, it has been recognized that these disorders, as well as systemic hyper-
tension, are associated with impaired  vasorelaxation12–15, diabetes mellitus, obesity, hypercholesterolemia or a 
sedentary lifestyle, enhancing the risk for endothelial dysfunction, atherosclerosis and systemic cardiovascular 
 diseases16.
The role of prediabetes and diabetes in the development and progression of vascular dysfunction and its 
complications is well documented in several arterial types and  organs17. However, there is less information 
available regarding the effects of these disorders on pulmonary vascular  function18. Taking this into account, 
we have investigated the effect of different stages of T2D on the contractile machinery and endothelial func-
tion in the pulmonary and systemic circulation and the molecular players involved. We observed that T2D 
progression differently affects endothelial function and vascular contractility in the aorta and PA, with diabetes 
affecting endothelial function earlier in the aorta than in the PA, suggesting that the latter is more resistant to 
diabetes-induced endothelial dysfunction. In the aorta we confirmed the well documented relationship between 
the nitrergic system—inflammation—oxidative stress and endothelial dysfunction while in the PA despite the 
involvement of all these mechanisms, a delayed disruption of the nitrergic system could protect these vessels in 
initial stages of dysmetabolism. Additionally, we found that in later stages of metabolic disease, in T2D animals, 
wall mineralization might contribute to aggravated endothelial dysfunction in the PA.
Methods
Ethical approval. All experiments and animal care were performed in accordance with the European 
Union Directive for Protection of Vertebrates Used for Experimental and Other Scientific Ends (2010/63/EU) 
and with the ARRIVE guidelines. Experimental protocols were approved by the Ethics Committee of NOVA 
Medical School/Faculdade de Ciências Médicas (nº18/2016/CEFCM) and by the Portuguese Authority for the 
animal Health (DGAV, Ref 0421/000/000/2016).
Animals and surgical procedures. Experiments were performed in 8 weeks old male Wistar rats (200–
490 g), obtained from the vivarium of NOVA Medical School, Faculdade de Ciências Médicas. Animals were 
housed in a controlled environment (21 ± 1 °C; 55 ± 10% humidity) with a 12-h light/dark cycle and free access 
to food and water. In this project we have used two diet-induced animal models: a prediabetes model obtained 
by submitting animals to a high-fat (HF) diet and an early-phase type 2 diabetes model obtained by submit-
ting animals to a high-fat and high-sucrose (HFHSu) diet. These animal models were compared with a control 
group that fed a standard diet (7.4% fat plus 75% carbohydrate [4% sugar] plus 17% protein; SDS diets RM1; 
Probiológica, Lisbon, Portugal; For a more detailed description see Table S1). The HF model fed a lipid-rich 
diet with 60% of energy from fat (61.6% fat + 20.3% carbohydrate + 19.1% protein; Mucedola, Milan, Italy; For a 
more detailed description see Table S2), during 3 weeks and the HFHSu model was obtained by a combination 
of a lipid-rich diet (61.6% fat + 20.3% carbohydrate + 19.1% protein; Mucedola, Milan, Italy) plus 35% (wt/vol.) 
sucrose (PanReac, Madrid, Spain), during 25 weeks. Body weight was weekly recorded meanwhile caloric and 
liquid intake were monitored daily in all groups of animals. Metabolic parameters as fasting glycemia, insulin 
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sensitivity and glucose tolerance were monitored throughout the experimental period by an insulin tolerance 
test (ITT) and an oral glucose tolerance test (OGTT), respectively. At the end of the experimental period, the 
rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and plasma was collected by heart puncture 
and then processed to measure NO levels. The aorta and the pulmonary arteries were excised and dissected for 
vascular function studies or stored for posterior analyses.
Insulin tolerance test. Insulin sensitivity was assessed by an ITT in conscious animals after an overnight 
fast. Briefly, the ITT was performed by administrating a bolus of insulin (0.1U/Kg) in the tail  vein19 and measur-
ing of the decline of glycemia in the next 15 min. Blood was collected via tail tipping and glycemia evaluated 
with a glucometer (Precision Xtra Meter, Abbott Diabetes Care, Portugal) and test strips (Abbott Diabetes Care, 
Portugal). The constant rate for plasma glucose decline  (KITT) was calculated as previously  described19.
Oral glucose tolerance test. OGTT evaluated the insulin released and the sensitivity of the peripheral 
tissue toward the insulin action. For the OGTT, the animals were fasted overnight and in the morning a bolus of 
glucose (2 g/kg) was administrated intragastrically by oral  gavage20. Blood samples were collected by tail tipping 
before (0 min) and 15, 30, 60, 120, 180 min after glucose administration. Glucose levels were measured as for the 
ITT. The product of the area under the curve (AUC) was used to estimate the glucose tolerance.
Plasma insulin levels measurement. Plasma insulin levels were determined with an enzyme-linked 
immunosorbent assay (ELISA) kit Mercodia Ultrasensitive Rat Insulin ELISA Kit (Mercodia AB, Uppsala, Swe-
den) as previously  described19.
Artery mounting and measurement of tension development. The physiological function of the 
arteries was studied using a small vessel wire myograph (DMT, Denmark), technique that allows ex vivo moni-
toring of isometric tension in response to different pathophysiological  stimuli21. The bath chambers for isolated 
arteries were maintained in normoxic conditions (gassing with a mixture of 5%CO2/21%O2/rest  N2) and at 37 
°C throughout the whole experimental procedure. Fresh conduit (aortic) and resistance (pulmonary) blood 
vessels were dissected in cold physiological salt solution (PSS) that contained the following (in mM): 118 NaCl, 
24  NaHCO3, 1  MgSO4, 0.435  NaH2PO4, 5.56 glucose, 1.8  CaCl2 and 4 KCl. Rings of aorta or PA were dissected 
under a dissection microscope and withdrawn of all adventitia and parenchyma. The arteries were mounted to 
measure changes in isometric tension using a force transducer, stabilized for 30 min and then stretched to give 
a basal tension of 5–6mN. To check the viability of the vessels were used three responses (3 min each) of PSS 
containing 80 mmol/L KCl (KPSS, isotonic replacement of NaCl by KCl), washing twice with PSS between them.
After washing out, arteries were constricted with cumulative concentrations of  PGF2α (0.03–10 µM or 30 µM; 
Bio-Techne, MN, USA) to study their contractile properties. In a subsequent step, selecting a sub-maximal  PGF2α 
concentration (according with the previous dose response curve), the vasorelaxant effect of acetylcholine was 
recorded (0.03–30 µM; Sigma-Aldrich, Madrid, Spain), as an index of endothelial integrity. Additionally, and 
to further study the contractile properties of the arteries a 1 µM concentration of phenylephrine (PE, Sigma-
Aldrich, Madrid, Spain) was added.
Western blot analyses of eNOS, iNOS,  PGF2α receptors, AGEs receptors, IL‑1 and IL‑6 recep‑
tors and catalase. For western blot analysis, approximately 10 mg of PA or aorta arteries were dissected and 
homogenized in liquid nitrogen and then placed in approximately 350ul of Zurich medium containing proteases 
inhibitors. Proteins (20 μg) were separated by electrophoresis in 10% sodium dodecylsulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), followed by transference to a nitrocellulose membrane (BioRad, Germany). 
The membranes were then blocked in I-Block solution (Applied Biosystems, Foster City, USA) during 1 h. After 
blocking, membranes were incubated overnight, at 4 °C, with the following primary antibodies: monoclonal 
mouse anti-eNOS (1:500; Santa Cruz Biotechnology, Madrid, Spain), polyclonal rabbit anti-iNOS (1:100; Santa 
Cruz Biotechnology, Madrid, Spain), polyclonal rabbit anti-Prostaglandin F2 alpha Receptor antibody (1:200; 
Santa Cruz Biotechnology, Madrid, Spain); polyclonal rabbit anti-AGEs receptor (1:500; TransGenic Inc., Kobe, 
Japan), polyclonal mouse anti-IL-1 receptor (1:50; Santa Cruz Biotechnology, Madrid, Spain), polyclonal mouse 
anti-IL-6 receptor (1:50; Santa Cruz Biotechnology, Madrid, Spain) or polyclonal goat anti-Catalase antibody 
(1:500; SICGEN, Coimbra, Portugal). Afterwards, membranes were incubated with biotin-conjugated goat anti-
rabbit IgG (1:10,000; Millipore, Madrid, Spain), mouse anti-goat IgG (1:10,000; Millipore, Madrid, Spain) or 
goat anti-mouse IgG (1:10,000; Millipore, Madrid, Spain), at room temperature for 90 min, and with horserad-
ish peroxidase-conjugated streptavidin (1:10,000, Thermo Scientific, USA), at room temperature for 30 min. 
Between incubations membranes were washed with TBS-T (0,01%) for 3 times, 5 min. Chemiluminescence sig-
nals were developed with enhanced chemiluminescence reagent (Clarity Western ECL, Bio-Rad, United States), 
the signal detected in a ChemiDoc Touch Imaging System (Chemidoc; BioRad, Madrid, Spain) and quantified 
using the Image Lab software (BioRad). The membranes were reprobed with goat anti-calnexin (1:1000; SicGen, 
Coimbra, Portugal), goat anti-β-Actin (1:1000; Santa Cruz Biotechnology, Madrid, Spain) or goat anti-GAPDH 
(1:1000; Santa Cruz Biotechnology, Madrid, Spain) to compare and normalize the expression of proteins with 
the amount of protein loaded.
AGEs (anti N‑(carboxyethyl) lysine quantification. Pulmonary and aorta arteries samples lysates were 
prepared as previously described for western blot analysis. For dot-blot method 5ug of protein from each sample 
was applied directly on nitrocellulose membrane on the dot-blot vacuum system and each well was washed with 
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TBST (137 mM NaCl, 2.7 mM KCl, 20 mM Tris, pH7.4, plus 0.1% Tween-20). The membrane was then removed 
from the dot-blot system and incubated with blocking buffer (BSA 5% in TBST) for 1 h at room temperature in 
a shaker. The membrane was incubated with primary antibody for AGEs (anti N-(carboxyethyl) lysine mono-
clonal antibody (1:500; Cosmobio Co., Ltd, Japan) overnight at 4 °C. The membrane was washed with TBS-T 
(0.01%) for 3 times, 5 min, and incubated with goat anti-mouse-HRP conjugated antibody (1:5000; Santa Cruz 
Biotechnology, Madrid, Spain) for 1 h at room temperature. Membrane was washed again and incubated with 
ECL substrate solution (Clarity Western ECL, Bio-Rad, United States) for chemiluminescence signal quantifi-
cation in a ChemiDoc Touch Imaging System (Chemidoc; BioRad, Madrid, Spain). For detection and quanti-
fication of the loading control the membrane was stripped off, washed TBS-T (0,01%) for 4 times and loading 
control was evaluated by incubating the membrane with primary antibody goat anti-calnexin (1:1000; SicGen, 
Coimbra, Portugal) for 1 h at room temperature, washed 3 times with TBS-T (0,01%) and incubated with mouse 
anti-goat (1:5000; BioRad, Madrid, Spain). Chemiluminescence signals were developed with enhanced chemi-
luminescence reagent (Clarity Western ECL, Bio-Rad, United States) and the signal detected in a ChemiDoc 
Touch Imaging System (Chemidoc; BioRad, Madrid, Spain) for chemiluminescence signal quantification using 
the Image Lab software (BioRad).
Nitric oxide and  PGF2α quantification. To quantify NO in pulmonary artery and in the aorta, the arter-
ies were dissected, homogenized in liquid nitrogen and subsequently transferred to a homogenization buffer 
(25 mM Tris HCL, 1 mM EDTA, 1 mM EGTA). Afterwards the homogenates were centrifuged at 13000 g (4 °C) 
for 20 min and the supernatant collected. For plasma NO quantification, blood was collected from a heart punc-
ture to EDTA-precoated tubes and centrifuged at 3000 g (4 °C) during 10 min. Plasma and artery homogenates 
were then deproteinized by diluting the samples with ethanol absolute at 4 °C (1:3). After 30 min on ice, samples 
were centrifuged in a microfuge (Eppendorf, Madrid, Spain) at 12000 g for 15 min. NO/NO3− concentration 
was determined by using a specific and sensitive NO/ozone chemiluminescence technique (NO-Analyzer 280, 
Sievers Research Inc., Boulder Colorado). For plasma  PGF2α quantification, blood samples were treated as men-
tioned above. Since some samples normally have very low levels of  PGF2α extraction with a C18 reverse phase 
column was performed for a more accurate measurement. After processing the samples,  PGF2α levels were meas-
ured through an in vitro competitive ELISA (Enzyme-Linked Immunosorbent Assay) kit (Abcam, Cambridge, 
United Kingdom).
Histochemical analysis of vascular mineralization. Aortas and PA were collected, dissected and 
immersion-fixed in PFA 4%. Samples were then embedded into paraffin (Sakura Finetek Europe B.V., Zoeter-
woude, Netherlands) and longitudinal serial sections of 3 μm thick were obtained with a Microtome Microm 
HM200 (MICROM Laborgeräte GmbH, ZEISS Group, Walldorf, Germany). After sectioned, the samples were 
transferred into slides and stained with hematoxylin and eosin, Masson’s trichrome (for collagen evaluation) and 
Taenzer-Unna Orcein (for elastin evaluation).
Aorta and PA lesions were examined by two pathologists blinded to experimental groups to avoid evalua-
tion biases and classified according to previously published  criteria22,23. A semiquantitative score of Hematoxy-
lin–Eosin staining slides was determined based on calcification in arterial cross section according to a 4-tier 
severity scale: 0, no calcification; 1, focal calcification spots; 2, partial calcification covering 20–80% of the arterial 
circumference; and 3, circumferential  calcification24. Cases with discrepancies were jointly re-evaluated until 
a consensus was reached. Representative photographs were acquired using NDP.view2 software (Hamamatsu, 
Japan) in slides digitally scanned in the Hamamatsu NanoZoomerSQ (Hamamatsu, Japan).
Statistical analysis. All data obtained for the present work was evaluated using Graph Pad Prism Software, 
version 8 (GraphPad Software Inc., USA) and presented as scatter plots or mean values with standard deviation 
(SD). Significance of the differences between the mean values was calculated by one-and two-way ANOVA with 
Bonferroni multiple comparison test. Differences were considered significant at p < 0.05.
Results
Effect of hypercaloric diets on metabolic variables. We have used two different types of hypercaloric 
diets, a 3 weeks HF diet and 25 weeks of HFHSu to achieve different stages of metabolic dysfunction in rats, 
namely a prediabetes stage and an early stage of type 2 diabetes, respectively. Metabolic parameters and evalu-
ation are summarised in Table 1. HF and HFHSu diet promoted a 24.7% and 102.6% increase in the caloric 
intake per day (control animals = 147.8 ± 816.5 kcal/day/kg), respectively, being this augmented intake reflected 
in animals weight gain: HF animals increased 0.26 ± 0.04 g/day and HFHSu animals 0.35 ± 0.03 g/day during diet 
period (weight gain control animals = 0.13 ± 0.04 g/day). As expected, although HF diet induced a state of meta-
bolic dysfunction, the metabolic alterations promoted by this diet are less intense than the alterations promoted 
by HFHSu diet: HF diet was incapable of promoting an increase in fasting glycemia, while HFHSu increased 
significantly glycemia values by 17.3%; HF diet decreased insulin sensitivity by 61.6% and increased glucose 
intolerance by 20.8% and plasma insulin levels by 67.7% while HFHSu diet exert more pronounced effects on 
insulin sensitivity, plasma insulin levels and glucose tolerance in comparison with the controls (Table 1).
Effect of hypercaloric diets on vascular contractility and endothelial function. Figure 1 shows 
a typical trace of the vascular contractile response to KPSS and cumulative doses of  PGF2α in the aorta (Fig. 1a) 
and PA (Fig. 1b). KPSS, an unspecific depolarizing stimulus, induced similar contractions in the PA and aorta 
of control or hypercaloric diet animals (data not shown). Contraction in response to 1 µM PE concentration 
showed no differences in either the PA or aorta in any of the disease states, prediabetes or early T2D, when com-
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pared with controls (Fig. 1c). We also tested 3 µM of PE in the aorta and there were no differences in vascular 
contractility among groups (data not shown). Because of the lack of differences among animals, and to further 
characterize the contractile properties of the arteries, we decided to use  PGF2α, at different concentrations, as 
contracting agent.  PGF2α increased vascular aorta and PA contractility in a dose dependent manner (Fig. 1d, e). 
In the aorta (Fig. 1d) contraction to  PGF2α was significantly enhanced in the HF animals (contraction to  PGF2α 
30 µM going from 75.3 ± 34.3% to 134.3 ± 54.4% of the KPSS contraction) while it did not changed in the HFHSu 
animals (contraction to  PGF2α 30 µM = 94.4 ± 44.1%). In the PA, contraction to  PGF2α 30 µM in control animals 
was 24.1 ± 16.2% of the KPSS response, while in HF animals it was enhanced to 32.0 ± 15.1% and diminished in 
the HFHSu (contraction to  PGF2α 30 µM = 10.6 ± 4.8%) (Fig. 1e).
Figure 2 shows the typical changes in wall tension of the aorta (Fig. 2a) and PA (Fig. 2b) by cumulative doses 
of ACh (0.03–30 µM), after precontraction with a stable submaximal  PGF2α contraction, matched among arteries. 
Table 1.  Effect of hypercaloric diets, high-fat (HF) and high fat-high sucrose (HFHSu), on caloric intake, 
weight gain, insulin sensitivity and glucose tolerance in rats. Animals were submitted to HF diet (60% lipid-
rich diet) during 3 weeks and to HFHSu (60% lipid-rich diet plus 35% sucrose in drinking water) during 
25 weeks. Insulin sensitivity was expressed as the constant of the insulin tolerance test,  KITT. Glucose tolerance 
was evaluated by an OGTT and depicted as the area under the curve of the glucose excursion curve. Results 
are presented as mean ± SD. One-way ANOVA with Dunnet’s Multiple Comparison test: *p < 0.05, **p < 0.01, 
***p < 0.001 and ****p < 0.0001 comparing hypercaloric diet groups with control group; #p < 0.05, ##p < 0.01 and 
####p < 0.0001 comparing HF and HFHSu groups.
CTL HF HFHSu
Weight increase (g/day) 0.13 ± 0.04 0.26 ± 0.04*** 0.35 ± 0.03****; ##
Caloric Intake (Kcal/day/kg) 147.8 ± 16.5 184.3 ± 6.89** 299.4 ± 18.08****; ####
Fasting Glycemia (mg/dl) 86.4 ± 5.08 85.2 ± 3.56 101.3 ± 7.87**
Glucose tolerance AUC glycemia (mg/dl*min) 20,063 ± 1271 24,234 ± 1183**** 25,392 ± 514.2****
Insulin sensitivity KITT (% glucose/min) 4.09 ± 0.42 1.57 ± 0.59**** 1.31 ± 0.12****
Insulin levels (pmol/l) 122.1 ± 75.25 378.4 ± 181.50* 737.1 ± 193.50***,#
Figure 1.  Effect of hypercaloric diets on vascular contractility in aorta and pulmonary artery (PA). Typical trace 
of aorta (a) and pulmonary artery (b) in response to a stimulus of KPSS 80 mM for 3 min, and a dose response 
curve to different concentrations of  PGF2α. (c) Average of the 3 min response to phenylephrine (PE) 1 µM (in PA 
(n = 15–52) and aorta (n = 9–16) of control, HF and HFHSu animal groups. (d) Dose response to  PGF2α (0.03–
10 µM) in aorta of control, HF and HFHSu (n = 10 for all) animals. (e) Dose response to  PGF2α (0.03–30 µM) 
in PA of control (n = 21), HF (n = 12) and HFHSu (n = 7) animals. Values are presented as mean ± SD. One-way 
ANOVA with Dunnet’s Multiple Comparison test. *p < 0.05, **p < 0.01 and ****p < 0.0001 versus control animals; 
#p < 0.05, ##p < 0.01, ###p < 0.001 and ####p < 0.0001, HF versus HFHSu animals.
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This protocol was used as a test of endothelial integrity, as ACh releases NO from the endothelial layer of the 
arteries, and its relaxation can be used as an index of vascular integrity. In the aorta (Fig. 2c), both animals sub-
mitted to hypercaloric diets showed signs of endothelial damage (contraction after ACh 30 µM of 20.1 ± 23.0% in 
controls vs 35.9 ± 31.1% in the HF and 45.5 ± 32.1% in the HFHSu animals). In the PA (Fig. 2d) it was observed 
a diminished endothelium dependent vasorelaxation in the HFHSu animals (remaining contraction to ACh 
30 µM 31.1 ± 21.8% in the controls vs 47.5 ± 17.8% in the HFHSu), which is a sign of endothelial damage, with 
no changes in the HF animals (with contraction after ACh 30 µM of 31.1 ± 28.0%). These data interestingly sug-
gest that PA shows a greater resistance to endothelial damage than aorta. In PA, the endothelium of HF animals 
seemed to remains undamaged and endothelial dysfunction only appears in the HFHSu animal model. In aorta, 
endothelial damage is already notable in HF animals, although to a smaller extent than in HFHSu animals.
Effect of diabetes progression on  PGF2α plasma levels and on the expression of  PGF2α recep‑
tors. PGF2α is a potent vasoconstrictor acting on the airways and on VSM cells to promote vasoconstriction 
and that has been implicated in the pathogenesis of  pulmonary25 and cardiovascular  disease26. Aiming to explore 
the alterations in the vasoconstrictor responses to  PGF2α in the aorta and PA produced by hypercaloric diets 
(Fig. 2c, d) herein we investigated the effects of diabetes progression on the levels of  PGF2α and on the expression 
of its receptors in aorta and PA (Fig. 3).
HF diet significantly increased  PGF2α levels in plasma by 130% in relation to control animals  (PGF2α control 
animals = 35.4 ± 22.1 pg/ml), while HFHSu diet only increased  PGF2α levels by 65% (Fig. 3a). In agreement with 
the increased levels of  PGF2α induced by HF diet, the expression of the  PGF2α receptor was decreased by 57.9% 
in the PA (Fig. 3b), although HFHSu diet did not modify the expression of  PGF2α receptor in this arterial wall. 
On the other side, in the aorta, HFHSu diet increased  PGF2α receptor expression by 17% while no alterations 
were observed in animals submitted to HF diet.
Effect of diabetes progression on systemic and local nitric oxide levels and on the expression 
of eNOS and iNOS. In Fig. 4 is represented the effect of diabetes progression, obtained by submitting the 
Figure 2.  Effect of type 2 diabetes progression on endothelial function in aorta and pulmonary artery (PA). 
Typical trace of a dose response relaxation curve to different concentrations of ACh (0.03–30 µM) in the 
aorta (a) and pulmonary artery (b). Average responses in the aorta (c) and pulmonary artery (d) of the dose 
response relaxations in control (n = 10–14), HF (n = 10–11) and HFHSu (n = 10) animals. Values are presented 
as mean ± SD. Curves compared using two-way ANOVA with Dunnet’s Multiple Comparison test. *p < 0.05 and 
**p < 0.01 versus control animals; #p < 0.05 and ##p < 0.01, HF versus HFHSu animals.
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animals to different hypercaloric diets during different times of exposure, on the levels of NO in the plasma and 
in aorta and PA, and on the expression of eNOS and iNOS in both arteries.
Both hypercaloric diets increased NO plasma levels, with the HF diet promoting a significant increase of 
160.3% and HFHSu inducing an even higher increase of 289% in the NO plasma levels in relation to controls 
(NO plasma levels in control animals of 10.2 ± 2.0 μM) (Fig. 4a left panel). When the NO levels were measured 
in both arteries, 3 weeks of exposure to HF diet were insufficient to promote significant alterations in the NO 
levels. However, HFHSu diet for 25 weeks increased NO levels by 50% in the aorta and by 93% in the PA when 
Figure 3.  Effect of prediabetes and early phase type 2 diabetes on PGF2α levels in plasma and on the expression 
of PGF2α receptor. (a) PGF2α levels in plasma of control animals (n = 6) and animals submitted to HF (n = 4) 
or HFHSu (n = 6) diets. (b) Average relative expression of PGF2α receptor (60KDa) and the loading protein 
β-Actin (43 kDa) or GAPDH (37 kDa) in aorta and pulmonary artery (PA) of control animals (n = 6) and 
animals submitted to HF (n = 6) and HFHSu (n = 6) diets. Representative western blots for each protein studied 
are depicted above the respective graphs. For PGF2α expression, the representative bands were cropped due 
to the sample order in the membrane. For complete membrane image see Supplementary data. Values are 
presented as scatter plots ± SD; One-way ANOVA with Dunnet’s comparison test. **p < 0.01 and ***p < 0.001 
versus control animals.
Figure 4.  Effect of type 2 diabetes progression on systemic and local nitric oxide levels and on the expression 
of eNOS and iNOS. Nitric oxide levels on plasma (a, left panel) and on aorta and pulmonary artery (a, right 
panel); Average expression of (b) iNOS (130 kDa) and (c) eNOS (140 kDa), and the loading proteins, calnexin 
(90 kDa) and β-Actin (43 kDa) in the aorta and PA of control (n = 6), HF (n = 5–6) and HFHSu (n = 6) animals. 
Representative western blots for each protein studied are depicted above the respective graphs. For eNOS 
expression, the representative bands were cropped due to the sample order in the membrane. For complete 
membrane image see Supplementary data. Values are presented as scatter plots ± SD; One-way ANOVA with 
Dunnet’s comparison test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 versus control animals; ##p < 0.01, 
###p < 0.001 and ####p < 0.0001 comparing the groups submitted to the hypercaloric diets.
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comparing with control animals (NO control aorta = 334.2 ± 51.3 nmoles/g tissue; NO control PA = 266.9 ± 52.0 nmoles/g 
tissue) (Fig. 4a right panel). In agreement with the increase in NO levels in the plasma and in the arteries, in 
the aorta both hypercaloric diets promoted an increase, of 23% and of 15%, for HF and HFHSu respectively, 
in iNOS. This increase of iNOS expression with both hypercaloric diets was also observed in the PA with an 
increase of 35% promoted by HF diet and of 70% promoted by the HFHSu diet (Fig. 4b). When eNOS expres-
sion was evaluated, it was observed an increase promoted by both hypercaloric diets in the aorta, 20% and 8% 
for HF diet and HFHSu diet, respectively, while only the HFHSu diet promoted an increase of 22% on eNOS 
expression in the PA in aorta (Fig. 4c).
Effect of diabetes progression on inflammatory markers involved in endothelial dysfunc‑
tion. Advanced glycation end products (AGEs) promote oxidative and inflammatory reactions in endothelial 
cells through the interaction with their receptor (RAGE)27. Herein, we observed that the levels of AGEs only 
increased in the aorta of the HFHSu animals by 75%, with no alterations on the PA (Fig. 5a). The expression of 
RAGE was significantly decreased by 19 and 32% in the aorta, respectively, with the HF and HFHSu diet, and by 
15%, in the PA with the HF diet, with no alterations observed in the PA with the HFHSu diet (Fig. 5b).
Inflammatory cytokines, such as interleukin-6 (IL-6) and 1 (IL-1), are considered as important contributors 
to endothelial dysfunction in  T2D10. Herein we evaluated IL-1 (Fig. 6a) and IL-6 receptors expression (Fig. 6b) in 
both arteries. In the aorta, hypercaloric diets, and specifically HFHSu decreased IL-1R by 23 and IL-6R by 35%. In 
contrast, in the PA both HF and HFHSu diets decreased IL-1R by 20 and 21%, although the decrease in HFHSu 
was not significant (p = 0.058). Surprisingly, in the PA, only HF diet decreased the expression of IL-6R by 26%.
Effect of diabetes progression on catalase expression. Catalase is an antioxidant enzyme that, 
conjugated with antibodies to platelet-endothelial cell adhesion molecule-1, specifically binds to endothelium, 
quenching reactive oxygen species, such as  H2O2, and alleviating vascular oxidative stress and  inflammation28. 
We evaluated the expression of this enzyme and observed that HF and HFHSu diets promoted a significant 
increase by 16 and 57%, respectively, in the aorta. In contrast HF diet promoted a decrease by 23% in the expres-
sion of catalase in the PA, while no alterations were found for animals submitted to HFHSu diet (Fig. 7).
Effect of diabetes progression on vascular mineralization. Vascular calcification is one of the major 
pathophysiological mechanisms on the basis of vascular disease, representing an independent risk factor for 
adverse outcomes. Through histological analysis of the arteries, stained with Hematoxylin and Eosin, it was 
possible to observe that no mineralization was present in the aorta arteries (Fig. 8a, top panel). However, miner-
Figure 5.  Effect of type 2 diabetes progression on AGEs levels and AGEs receptor expression. (a) Average 
relative levels of AGEs, and the loading protein Calnexin, on aorta and PA of control animals (n = 3–4) 
and animals submitted to HF (n = 3–4) or HFHSu (n = 6–8) diets. (b) Average relative expression of RAGE 
(42 kDa) and the loading protein used—Calnexin (90 kDa) or GAPDH (37 kDa)—in aorta and PA of control 
animals (n = 4–5) and animals submitted to HF (n = 4–5) and HFHSu (n = 4–5) diets. Representative western 
blots for each protein studied are depicted above the respective graphs. For complete membrane image see 
Supplementary data. Values are presented as scatter plots ± SD; One-way ANOVA with Dunnet’s comparison 
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alization was observed in the PA of some control and HF animals and in the PA of all HFHSu animals (Fig. 8a, 
Figure 6.  Effect of prediabetes and early phase type 2 diabetes on inflammatory markers involved in endothelial 
dysfunction. Average expression of (a) IL-1 receptor (IL-1R, 80 kDa) and (b) IL-6 receptor (IL-6R, 80 kDa) and 
the loading protein GAPDH (37 kDa) in aorta and pulmonary artery (PA) of control (n = 4–5), HF (n = 3–5) 
and HFHSu (n = 3–4) animals. Representative western blots for each protein studied are depicted above the 
respective graphs. Representative bands were cropped due to the sample order in the membrane. For complete 
membrane image see Supplementary data. Values are presented as scatter plots ± SD; One-way ANOVA with 
Dunnet’s comparison test. *p < 0.05 and **p < 0.01 versus control animals.
Figure 7.  Effect of prediabetes and early phase type 2 diabetes on catalase expression. Average expression of 
catalase (60 kDa), and the loading protein calnexin (90 kDa) in the aorta and pulmonary artery (PA) of control 
(n = 4–6), HF (n = 4) and HFHSu (n = 4) animals. Representative western blots for each protein studied are 
depicted above the respective graphs. The representative bands were cropped due to the sample order in the 
membrane. For complete membrane image see Supplementary data. Values are presented as scatter plots ± SD; 
One-way ANOVA with Dunnet’s comparison test. *p < 0.05 and **p < 0.01 versus control animals.
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Figure 8.  Effect of prediabetes and early phase type 2 diabetes on vascular mineralization. Histological analysis 
of the arteries stained with Hematoxylin and Eosin staining. No mineralization was observed on the aorta of the 
control, HF and HFHSu animals (a, top panel; left to right images, respectively). Mineralization was observed in 
the PA of various control and HF animals and in the PA of all the HFHSu animals (a, bottom panel; left to right 
images, respectively). (b) Vascular mineralization levels in PA of control (n = 7), HF (n = 4) and HFHSu (n = 8) 
animals. (c) Masson’s trichrome staining for collagen evaluation. No alterations were observed on collagen in 
the aorta of the control, HF and HFHSu animals (c, top panel; left to right images, respectively) nor in the PA 
of the control, HF and HFHSu animals (c, bottom panel; left to right images, respectively). (d) Taenzer-Unna 
Orcein staining for elastin evaluation. No alterations were observed on elastin in the aorta of the control, HF 
and HFHSu animals (d, top panel; left to right images, respectively) nor in the PA of the control, HF and HFHSu 
animals (d, bottom panel; left to right images, respectively). Values are presented as mean ± SD. One-way 
ANOVA with Dunnet’s comparison test. **p < 0.01 versus control animals.
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bottom panel). Vascular mineralization was classified using a scoring system, from 0 to 3, that is based on the 
sum of the distribution and the layers/extent of deposition (Table 2). We observed that the score of mineraliza-
tion was significantly higher in the HFHSu animals (mean score in control animals of 0.71 ± 0.76 and in the 
HFHSu of 1.88 ± 0.35) (Fig. 8b). Through Masson’s trichrome and Taenzer-Unna Orcein staining, collagen and 
elastin were evaluated. However, no significant alterations were observed after the hypercaloric diets neither in 
collagen in the aorta (Fig. 8c, top panel) or in the PA (Fig. 8c, bottom panel) nor in the elastin in aorta (Fig. 8d, 
top panel) or PA (Fig. 8d, bottom panel).
Discussion
Herein we found that T2D progression differently affects endothelial function and vascular contractility in the 
aorta and PA, with the contractile machinery being altered in the aorta and PA in prediabetes (HF animals) 
and in the PA of early stage T2D animals (HFHSu). Additionally, endothelial function was compromised in the 
aorta in both HF and HFHSu animals but only affected in the PA of HFHSu animals, suggesting that the PA is 
more resistant than aorta to endothelial dysfunction in early stages of disease progression. We found that PA and 
systemic endothelial dysfunction in diabetes progression in rats were associated with gradual alterations in the 
nitrergic system and inflammatory and oxidative pathways and we also described that PA dysfunction in T2D 
also involves endothelial wall mineralization.
Complex structural and functional changes occur in the arterial system with diabetes. We tested several 
vasoconstricting agents to study the influence of T2D progression on pulmonary and systemic vascular contrac-
tion. Phenylephrine did not change vascular contraction in any of the concentrations tested in both arteries, 
suggesting that sympathetic control of vascular contractility is not altered in the diabetic disease states evalu-
ated in the present study (Fig. 1c). This contrasts with the findings that patients with T2D exhibited heightened 
norepinephrine-mediated vasoconstriction due to an increased alpha-adrenoreceptors for their level of systemic 
sympathetic nervous system  activity29. However, these differences might reflect the low glucose levels of our 
animal models (Table 1) in comparison with T2D patients as well as the stage of disease progression.  PGF2α was 
also used, at different concentrations, to study vascular contractility and as contracting agent to study endothe-
lial function. PGF2α is known to promote resistance artery constriction through prostaglandin F2α receptor 
in smooth muscle cells, leading eventually to increased blood  pressure26. Herein,  PGF2α increased vascular PA 
contractility in a dose dependent manner in HF animals and diminished in a dose dependent manner in the 
HFHSu. In the aorta contraction to  PGF2α was significantly enhanced in the HF animals while slightly increased, 
although not significantly, in the HFHSu animals. This increase in vascular contractility in HF animals, both 
in aorta and PA, is in accordance with findings showing that elevated glucose increases contractile responses 
in vascular smooth muscle  cells30,31 and with the increased plasma  PGF2α levels described herein (Fig. 3a) that 
can contribute to the increased contractility. In the PA, this was accompanied by a decrease in the expression of 
 PGF2α receptors (Fig. 3b), suggesting a compensation of the system to the increased  PGF2α plasma levels however, 
this compensation might be not enough to maintain vascular PA contractility in HF animals. In fact, we cannot 
rule out that alterations in other constrictor factors, as endothelin-1, might contribute to the increased  PGF2α 
Table 2.  Effect of hypercaloric diets, high-fat (HF) and high fat-high sucrose (HFHSu), on pulmonary 
artery mineralization. Vascular mineralization was classified using a scoring system, determined based on 
calcification in arterial cross section according to a 4-tier severity scale: 0, no calcification; 1, focal calcification 
spots; 2, partial calcification covering 20–80% of the arterial circumference; and 3, circumferential calcification.
Experimental group Pathology findings Score (distribution)
CTL
Mineralization, intimal, focal 1
No changes 0
Mineralization, intimal, focal 1
Mineralization, intimal and subintimal, multifocal 2
No changes 0
No changes 0





Mineralization, intimal, focal 1
HFHSu
Mineralization, intimal, subintimal and adventitia, multifocal 2
Mineralization, intimal, multifocal 2
Mineralization, intimal, multifocal 2
Mineralization, intimal, multifocal 2
Mineralization, intimal, multifocal 2
Mineralization, intimal, multifocal 2
Mineralization, intimal and media, multifocal 2
Mineralization, intimal, focal 1
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vasoconstrictor responses in both aorta and PA. Vascular contractility to  PGF2α in HFHSu animals was lower in 
the PA in comparison with control animals, being similar in the aorta (Fig. 1d–e). These differences from HF to 
HFHSu animals might reflect adaptations of arterial walls to maintain vascular integrity, as seen by the unaltered 
 PGF2α levels in blood (Fig. 3a) and in the levels of their receptors in the arteries (Fig. 3b). From the several fac-
tors contributing to altered vascular contractility responses, one is arterial calcification that leads to increased 
mechanical vessel rigidity and  stiffness32. Herein, we described that the PA of HFHSu animals exhibit increased 
artery mineralization with the development of intima and multifocal thickening (Fig. 6), changes not seen in the 
aorta. These differences in mineralization between the two arteries suggest that this is one of the mechanisms 
contributing to the changes in the vascular PA mechanical properties in HFHSu that is not occurring in the aorta.
Impaired endothelium-dependent vasodilation has been described in several vascular beds of different animal 
models of diabetes and in diabetic patients, including the aorta (for a review see Avogaro et al., 2011)17, however 
how T2D diabetes progression affects endothelium-dependent vasodilation and the endothelium-derived relaxing 
factors involved in PA dysfunction are less known. In the PA, ACh-dependent vasorelaxation, after precontrac-
tion with a stable submaximal  PGF2α concentration, did not change with HF diet, but decreased in HFHSu ani-
mals (Fig. 2d) while in the aorta, ACh-induced vasodilation gradually decreases with disease progression, with 
HFHSu animals exhibiting a lower vasodilatation than HF than the controls (Fig. 2d), which suggest that these 
two vascular beds respond differently to hypercaloric stimulus being PA more resistant to endothelial dysfunc-
tion. One of the major mechanisms that have been shown to be involved in systemic endothelial dysfunction in 
diabetes is an impairment of signal transduction or substrate availability of  NO33,34, which contrasts with our data 
that shows increased NO levels in plasma and in HFHSu aorta samples (Fig. 4a).The source of these increased 
NO levels is the augmented expression of iNOS and eNOS (Fig. 4b–c), reflecting an inflammatory-induced NO 
production. Similar to iNOS, some authors found that eNOS by binding to calcium-calmodulin at basal  Ca2+ 
levels in cytokine-treated endothelial cells, enhances its basal activity and is activated independently of increased 
 [Ca2+]i35. So, not only iNOS- but also eNOS-derived NO becomes prominent under inflammatory conditions 
and in fact, it has been seen that eNOS can be activated by IL-636. The role of endothelium-derived NO in the 
vascular function in the PA is poorly understood. Evidences suggest that NO is at least partially responsible for 
resting pulmonary  vasorelaxation37 and some studies suggest that a deregulation on NO production, associated 
with either an increase or decrease on eNOS expression, is present in pulmonary  hypertension38–40. In agree-
ment with the presence of a decreased ACh-dependent vasorelaxation in HFHSu animals in the PA showed 
herein (Fig. 2c), we observe increased levels of NO in this arterial wall (Fig. 4a right panel), that were due to 
increased iNOS and eNOS expression (Fig. 4b–c), suggesting that these NO levels correspond to inflammatory 
NO. Additionally, while iNOS expression increased with disease progression, eNOS alterations were not found 
in HF animals (Fig. 4c), suggesting that this might be one of the mechanisms involved in the protection of PA 
endothelial function in an initial stage of the disease.
Another mechanism postulated to be involved in the link between diabetes and vascular complications is the 
increased formation of AGEs. The binding of AGEs to their receptors has been shown to enhance oxidant stress 
and induce increased vascular permeability and reduced NO-dependent  vasodilation8. Herein, we observed 
that AGEs levels only increase in the aorta in HFHSu animals with no alterations promoted by 3 weeks of HF in 
both arteries or by HFHSu in the PA (Fig. 5a). Additionally, we described that the expression of AGE receptor, 
progressively diminished in the aorta with disease development being also significantly decreased in the PA with 
the HF diet (Fig. 5b). Altogether these results indicate a progressive inflammatory state. The increase in circulat-
ing and tissue AGEs levels was already demonstrated in both animal and human studies of  diabetes41–43. In fact, 
in animal models of diabetes, AGEs levels increase with the progression of the disease, reflected by augmented 
levels in kidneys, skin, and vascular  tissue43. Furthermore, it was already demonstrated that the increase in serum 
AGEs is correlated with the degree of impairment of endothelium-dependent and -independent vasodilation in 
patients with  T2D8. Although our data, in the aorta, is in agreement with the literature, no correlation between 
AGE levels, RAGE expression and disease progression was seen in the PA, suggesting compensatory mechanisms 
during more prolonged exposure to hypercaloric diets (HFHSu vs HF) or the involvement of other inflamma-
tory mediators. Another two inflammatory mediators that are deeply involved in endothelial dysfunction are 
IL-1 and IL-610, being the increase in these cytokines levels well reported in response to hypercaloric diets in 
animals and in T2D  patients44,45. In agreement, we found that in general, IL-1R and IL-6R expression in the aorta 
and PA decrease progressively with disease development (Fig. 6), suggesting higher levels of the corresponding 
cytokines. Confirming the inflammatory involvement in endothelial dysfunction, IL-1R and IL-6R expression 
follow the same pattern of expression than RAGE in both aorta and PA, this being an expected result as it is well 
described that AGE-RAGE interaction modulates the generation of pro-inflammatory molecules and pathways 
in endothelial cells in several diseases, including  diabetes46,47. Apart from the modulation of inflammation, 
AGE-RAGE interaction also modulates the generation of reactive oxygen  species46,48 these last mediators also 
contributing for endothelial  dysfunction7,8. In agreement with this, we found that the expression of catalase, an 
antioxidant enzyme that alleviates vascular oxidative stress and  inflammation28 increase gradually with disease 
progression in the aorta, suggesting a compensatory mechanism to overcome the increase in reactive oxygen 
species produced by hypercaloric diets. In contrast in the PA, there was a decrease in catalase expression with 
the HF diet (Fig. 7), which together with decreased AGE-RAGE signalling, might suggest that ROS levels are 
diminished in this arterial wall being this another mechanism contributing to maintain PA wall integrity in 
early phases of diabetes. The absence of significant molecular alterations in the PA in a more advanced disease 
state, in the HFHSu animals, together with the existence of a low contractility (Fig. 1) and low relaxation (Fig. 2) 
suggests that other major mechanisms as the vascular wall calcification (Fig. 8) play a more important role in 
endothelial dysfunction.
We conclude that T2D progression differently affects endothelial function and vascular contractility in the 
aorta and PA, being the PA more resistant to endothelial dysfunction than the aorta. Altogether our findings 
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show that the balance between the nitrergic system, inflammatory signals and reactive oxygen species are crucial 
to understand and discriminate the differences between these two arteries during metabolic disease progression. 
This can lead to significant advances in both preventative and therapeutic treatments in early stages of metabolic 
disease associated with PA endothelial dysfunction.
 Data availability
The data that support the findings of this study are available from the corresponding author upon request.
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